CC
ABCL icon

Casdin Capital’s AbCellera Biologics ABCL Stock Holding History

Casdin Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,360,129
Closed -$10.7M – 39
2024
Q1 		$10.7M Hold
2,360,129
– – 0.79% 24
2023
Q4 		$13.5M Hold
2,360,129
– – 1.32% 18
2023
Q3 		$10.9M Sell
2,360,129
-159,871
-6% -$973K 1.2% 21
2023
Q2 		$16.3M Hold
2,520,000
– – 1.42% 23
2023
Q1 		$19M Buy
2,520,000
+250,000
+11% +$2.27M 1.57% 18
2022
Q4 		$23M Buy
2,270,000
+620,000
+38% +$7.16M 1.78% 15
2022
Q3 		$16.3M Buy
1,650,000
+900,000
+120% +$9.87M 1.07% 20
2022
Q2 		$7.99M Buy
+750,000
New +$6.35M 0.68% 26
2021
Q1 		– Sell
-200,000
Closed -$8.05M – 49
2020
Q4 		$8.05M Buy
+200,000
New +$9.15M 0.24% 45

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Casdin Capital's ABCL Position: Q2 2024 in Review

Casdin Capital sold out of AbCellera Biologics (ABCL) in Q2 2024, closing a stake of 2,360,129 shares — an estimated $10.7M sold.

Casdin Capital first reported a position in ABCL in Q4 2020 and held it in 9 quarters. The position peaked at $23M in Q4 2022. 147 funds tracked by Wall St. Rank hold ABCL as of Q2 2024.

  • Casdin Capital reported no remaining AbCellera Biologics position as of Q2 2024 after selling out during the quarter.
  • Casdin Capital sold 2,360,129 AbCellera Biologics shares in Q2 2024, an estimated $10.7M.
  • Casdin Capital first reported a position in AbCellera Biologics in Q4 2020 and held it in 9 quarters.
  • Casdin Capital's AbCellera Biologics position peaked at $23M in Q4 2022.
  • 147 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2024.

Based on Casdin Capital's 13F filing for Q2 2024, filed 14 Aug 2024.